Pfizer said on Monday it has discontinued development of experimental weight-loss pill danuglipron after a trial patient ...

Pfizer's strong R&D pipeline, 7.5%+ dividend yield, & undervalued PE ratio make PFE stock a compelling investment opportunity ...

In 2024, the FDA's Center for Drug Evaluation and Research (CDER) approved 50 new drugs. The CDER director, Patrizia ...

Pfizer has encountered many setbacks in its quest to launch a medicine that could rival Wegovy and Zepbound. One of its ...

Johnson & Johnson’s Joaquin Duato is no longer the highest paid CEO in pharma. Meanwhile, just two women make the top 10.

Pfizer (PFE) stock slips as the company halts development of danuglipron for weight loss due to liver injury concerns. Read ...

Leveraging Trump’s impending tariffs, pharma companies have called on Europe again to change regulation, threatening a US ...

Pfizer has stopped the development of its weight loss pill after a patient experienced a liver injury that was potentially ...

Pfizer will halt its development of a weight-loss drug that was being closely watched by investors, in a significant blow to the US pharmaceutical group. The company said on Monday that it would stop ...

Pfizer on Monday announced it is halting development of a daily weight loss pill after one patient experienced a liver injury ...

One of the firms setting out its vision for our digital future is Pfizer. Its chief digital and technology officer Lidia Fonseca offered a fascinating insight into how one biggest pharmaceutical ...

Americans may end up paying more for their medicines as well as facing shortages of drugs they need. So it's possible there ...